Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million -$225 million (previously $180 million -$200 million) and adjusted earnings per diluted share increased to $6.70 -$7.00 (previously $6.00 -$6.25) 1 Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., August 7, 2025 – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today r ...